Prodrug modification increases potassium tricyclo[5.2.1.0(2,6)]-decan-8-yl dithiocarbonate (D609) chemical stability and cytotoxicity against U937 leukemia cells.
D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology*; D001952:Bridged-Ring Compounds / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects; D002518:Ceramides / Q000378:metabolism; D015195:Drug Design; D004355:Drug Stability; D004950:Esterases / Q000378:metabolism; D006801:Humans; D006868:Hydrolysis; D007938:Leukemia / Q000473:pathology; D009636:Norbornanes; D011355:Prodrugs / Q000378:metabolism / Q000494:pharmacology*; D013859:Thiocarbamates; D013871:Thiones / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D020298:U937 Cells
D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D002518:Ceramides; D009636:Norbornanes; D011355:Prodrugs; D013859:Thiocarbamates; D013871:Thiones; C046498:tricyclodecane-9-yl-xanthogenate; D004950:Esterases